GCI Health adds senior healthcare talent to roster
31 August, 2011
— GCI Health, a leading healthcare public relations agency, today announced the appointment of three seasoned account leaders — Senior Vice President Catherine Falcetti, Vice President Julie Fleisher and Vice President Robyn Leventhal.
“GCI Health continues to aggressively expand our best-in-class team by recruiting new talent to anticipate changing client needs and new opportunities,” said Wendy Lund, CEO, GCI Health. “The addition of Catherine, Julie and Robyn is part of the agency’s commitment to cultivating diverse and exceptional client service.”
Falcetti joins the New York office after 11 years at MS&L, where she served as Senior Vice President in Healthcare. Falcetti’s pharmaceutical experience includes leading business for Roche, Eli Lilly, Johnson & Johnson, Daiichi Sankyo and Genentech. Falcetti has also directed integrated marketing for award-winning campaigns supporting consumer products as well as corporate sponsorships of Olympic Games, professional sports and entertainment properties. At GCI Health, Falcetti will continue to focus on pharma with specialized, blockbuster and OTC drugs.
Fleisher will add to GCI Health’s diverse talent pool with her expertise in pharmaceutical and vaccine communications. Most recently, she served as Vice President, Corporate Communications, at Ruder Finn. In this role, she developed and implemented global PR programs for Novartis Vaccines meningitis and influenza franchises. Previously, Fleisher assisted with high-profile consumer campaigns for Amgen and Pfizer’s Enbrel, as well as executed global programs for Pfizer’s Prevenar while at Porter Novelli. She also helped support AstraZeneca’s oncology franchise for the Zeno Group.
Leventhal brings rich experience in rare and complicated diseases and deep experience leading communications efforts surrounding FDA regulatory milestones. Formerly a Vice President at MS&L, Leventhal played a key role in FDA Advisory Committee meetings and subsequent approvals for Genentech’s Actemra and EMD Serono’s Egrifta. Leventhal spent many years supporting Roche’s virology portfolio, including Fuzeon, Invirase and Pegasys, and is passionate about working with HIV/AIDs and HCV communities. Prior to MS&L, Leventhal supported consumer education for Pfizer’s Chantix and AstraZeneca’s Seroquel at Edelman.
With this ongoing expansion of dynamic healthcare expertise, the agency continues to strive to meet and exceed the standard of excellence, which garnered the 2011 Healthcare Agency of the Year by The Holmes Report and a 2011 SABRE award for Pharmaceutical Rx Campaign of the Year.Contact
Nicole Zerillo, GCI Health
+1 (212) 798-9914 email@example.com About GCI Health
GCI Health is a forward-thinking healthcare public relations agency powered by “best-in-the-business” professionals and is the only WPP company that specializes in healthcare public relations. With more than 80 professionals in offices in New York, Atlanta, Los Angeles, San Francisco, Boston, Chicago, Toronto and the U.K., GCI Health offers clients an accessible senior level leadership team, A-to-Z healthcare experience, a commitment to “beating” client expectations, and an obsession with anticipating the challenges of an increasingly complex and transforming healthcare communications environment. With insider’s knowledge of health media, high science, digital health strategy, consumer activation, crisis management, patient advocacy and health education, GCI Health’s focus on delivering results is unrelenting. For more information, please visit http://www.gcihealth.com